The American College of Cardiology/American Heart Association (ACC/AHA) recommends the measurement of post-PCI biomarkers to determine PMI and evaluate the outcome of treatment (4, 11, 12) The European Society of Cardiology (ESC) recommends measuring the hs-CRP level as a part of the risk assessment program for patients with the risk of cardiovascular disease (class II b) (1, 13). The gene discussed is CRP; the disease is cardiovascular disorder.